Plasma miR‑15b‑5p and miR‑590‑5p for distinguishing patients with bladder cancer from healthy individuals

  • Authors:
    • Angelika Tölle
    • Laura Buckendahl
    • Klaus Jung
  • View Affiliations

  • Published online on: July 24, 2019     https://doi.org/10.3892/or.2019.7247
  • Pages: 1609-1620
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs (miRNAs/miRs) act as markers for various cancers, including bladder cancer (BC). Plasma miRNAs are potential biomarkers for the noninvasive diagnosis and long‑term surveillance of BC. The aim of the present study was to identify diagnostically reliable miRNAs in the plasma and examine their potential monitoring capacity. miRNAs were measured by reverse transcription‑quantitative polymerase chain reaction. The study was performed as a discovery phase, which included plasma samples from each of the 10 patients with and without BC prior to transurethral resection (TURB). The results were validated in a second phase, involving 36 patients with plasma samples collected before the second TURB or radical cystectomy (RC), and after RC. During the discovery step, three elevated miRNAs (miR‑15b‑5p, miR‑590‑5p, miR‑29b‑3p) and two decreased miRNAs (miR‑10b‑5p, miR‑144‑5p) were selected as potential miRNA candidates for further validation. miR‑15b‑5p and miR‑590‑5p were finally confirmed to discriminate between cancer cases and controls; however, for disease monitoring of BC, both miRNAs were not suitable as a decline in the miRNA levels was not observed in some patients after tumor removal. Our results suggested that circulating miR‑15b‑5p and miR‑590‑5p have useful diagnostic potential for BC, but are rather unsuitable as monitoring markers for disease. The reasons of this apparent contradictory observation may be due to the aspect of biological variation of circulating miRNAs and serial measurements could be unreliable.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, et al: EAU Guidelines on Non-Muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Pandith AA, Shah ZA and Siddiqi MA: Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol. 31:398–406. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Wu XR: Biology of urothelial tumorigenesis: Insights from genetically engineered mice. Cancer Metastasis Rev. 28:281–290. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Kim WJ and Bae SC: Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 99:646–652. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Etheridge A, Lee I, Hood L, Galas D and Wang K: Extracellular microRNA: A new source of biomarkers. Mutat Res. 717:85–90. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Zen K and Zhang CY: Circulating microRNAs: A novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 32:326–348. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Adam L, Wszolek MF, Liu CG, Jing W, Diao L, Zien A, Zhang JD, Jackson D and Dinney CP: Plasma microRNA profiles for bladder cancer detection. Urol Oncol. 31:1701–1708. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P and Yu Z: miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res. 33:672014. View Article : Google Scholar : PubMed/NCBI

10 

Feng Y, Kang Y, He Y, Liu J, Liang B, Yang P and Yu Z: microRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer. BMC Urol. 14:502014. View Article : Google Scholar : PubMed/NCBI

11 

Du M, Shi D, Yuan L, Li P, Chu H, Qin C, Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Rep. 5:104372015. View Article : Google Scholar : PubMed/NCBI

12 

Fang Z, Dai W, Wang X, Chen W, Shen C, Ye G and Li L: Circulating miR-205: A promising biomarker for the detection and prognosis evaluation of bladder cancer. Tumour Biol. 37:8075–8082. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Motawi TK, Rizk SM, Ibrahim TM and Ibrahim IA: Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis. Cell Biochem Funct. 34:142–148. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Tölle A, Blobel CC and Jung K: Circulating miRNAs in blood and urine as diagnostic and prognostic biomarkers for bladder cancer: An update in 2017. Biomark Med. 12:667–676. 2018. View Article : Google Scholar : PubMed/NCBI

15 

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 127:118–126. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Wittekind C, Asamura H and Sobin LH: TNM Atlas. Hoboken. (New Jersey, US, Wiley-Backwell Publishing). 2014. View Article : Google Scholar

18 

Shah JS, Soon PS and Marsh DJ: Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs. PLoS One. 11:e01532002016. View Article : Google Scholar : PubMed/NCBI

19 

Blondal T, Jensby NS, Baker A, Andreasen D, Mouritzen P, Wrang Teilum M and Dahlsveen IK: Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 59 (Suppl):S1–S6. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF and Tewari M: Blood cell origin of circulating MicroRNAs: A cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 5:492–497. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N and Reid G: The impact of hemolysis on cell-free microRNA biomarkers. Front Genet. 4:942013. View Article : Google Scholar : PubMed/NCBI

22 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

23 

Fraser CG: Biological variation-from principles to practice. Washington. (DC, U.S., AACC Press). 2001.

24 

Ammerlaan W and Betsou F: Intraindividual temporal miRNA variability in serum, plasma, and white blood cell subpopulations. Biopreserv Biobank. 14:390–397. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Ciesla M, Skrzypek K, Kozakowska M, Loboda A, Jozkowicz A and Dulak J: MicroRNAs as biomarkers of disease onset. Anal Bioanal Chem. 401:2051–2061. 2011. View Article : Google Scholar : PubMed/NCBI

26 

Wang W, Peng B, Wang D, Ma X, Jiang D, Zhao J and Yu L: Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer. 129:1624–1634. 2011. View Article : Google Scholar : PubMed/NCBI

27 

Huang X, Liang M, Dittmar R and Wang L: Extracellular microRNAs in urologic malignancies: Chances and challenges. Int J Mol Sci. 14:14785–14799. 2013. View Article : Google Scholar : PubMed/NCBI

28 

MacLellan SA, MacAulay C, Lam S and Garnis C: Pre-profiling factors influencing serum microRNA levels. BMC Clin Pathol. 14:272014. View Article : Google Scholar : PubMed/NCBI

29 

Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, et al: miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 15:695–705. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W and Li H: Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev. 11:905–911. 2010.PubMed/NCBI

31 

Zhao F, Ge YZ, Zhou LH, Xu LW, Xu Z, Ping WW, Wang M, Zhou CC, Wu R and Jia RP: Identification of hub miRNA biomarkers for bladder cancer by weighted gene coexpression network analysis. Onco Targets Ther. 10:5551–5559. 2017. View Article : Google Scholar : PubMed/NCBI

32 

Wang C, Chen L, Yang Y, Zhang M and Wong G: Identification of bladder cancer prognostic biomarkers using an ageing gene-related competitive endogenous RNA network. Oncotarget. 8:111742–111753. 2017. View Article : Google Scholar : PubMed/NCBI

33 

Armstrong DA, Green BB, Seigne JD, Schned AR and Marsit CJ: MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer. Mol Cancer. 14:1942015. View Article : Google Scholar : PubMed/NCBI

34 

Xie Y, Ma X, Chen L, Li H, Gu L, Gao Y, Zhang Y, Li X, Fan Y, Chen J, et al: MicroRNAs with prognostic significance in bladder cancer: A systematic review and meta-analysis. Sci Rep. 7:56192017. View Article : Google Scholar : PubMed/NCBI

35 

Friedel R, Diederichs F and Lindena J: Advances in clinical enzymology. Basel, S. Karger AG; Switzerland: 1979, pp. 70–105

36 

Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, Jung V, Becker F, Herrmann E, Walgenbach-Brunagel G, von Ruecker A, et al: Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol. 36:391–394. 2012. View Article : Google Scholar : PubMed/NCBI

37 

Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brunagel G, von Ruecker A, Muller SC, et al: MicroRNAs in renal cell carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI

38 

Fendler A, Stephan C, Yousef GM, Kristiansen G and Jung K: The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 13:734–752. 2016. View Article : Google Scholar : PubMed/NCBI

39 

White MC, Holman DM, Boehm JE, Peipins LA, Grossman M and Henley SJ: Age and cancer risk: A potentially modifiable relationship. Am J Prev Med 46 (3 Suppl 1). S7–S15. 2014. View Article : Google Scholar

40 

Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, Hamdy FC and Catto JW: An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer. 107:123–128. 2012. View Article : Google Scholar : PubMed/NCBI

41 

Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, Qu A, Zhang X, Pan H, Yang Y and Wang C: Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer. 136:854–862. 2015. View Article : Google Scholar : PubMed/NCBI

42 

Binderup HG, Madsen JS, Heegaard NHH, Houlind K, Andersen RF and Brasen CL: Quantification of microRNA levels in plasma-Impact of preanalytical and analytical conditions. PLoS One. 13:e02010692018. View Article : Google Scholar : PubMed/NCBI

43 

Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A and Galandiuk S: A plasma microRNA panel for detection of colorectal adenomas: A step toward more precise screening for colorectal cancer. Ann Surg. 258:400–408. 2013. View Article : Google Scholar : PubMed/NCBI

44 

Chen Y, Chen J, Liu Y, Li S and Huang P: Plasma miR-15b-5p, miR-338-5p, and miR-764 as biomarkers for hepatocellular carcinoma. Med Sci Monit. 21:1864–1871. 2015. View Article : Google Scholar : PubMed/NCBI

45 

Fogli S, Polini B, Carpi S, Pardini B, Naccarati A, Dubbini N, Lanza M, Breschi MC, Romanini A and Nieri P: Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol. 39:10104283177016462017. View Article : Google Scholar : PubMed/NCBI

46 

Wang F, Zu Y, Zhu S, Yang Y, Huang W, Xie H and Li G: Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression. Biochem Biophys Res Commun. 507:231–235. 2018. View Article : Google Scholar : PubMed/NCBI

47 

Zhao C, Li Y, Chen G, Wang F, Shen Z and Zhou R: Overexpression of miR-15b-5p promotes gastric cancer metastasis by regulating PAQR3. Oncol Rep. 38:352–358. 2017. View Article : Google Scholar : PubMed/NCBI

48 

Summerer I, Niyazi M, Unger K, Pitea A, Zangen V, Hess J, Atkinson MJ, Belka C, Moertl S and Zitzelsberger H: Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol. 8:2962013. View Article : Google Scholar : PubMed/NCBI

49 

Yu M, Luo Y, Cong Z, Mu Y, Qiu Y and Zhong M: MicroRNA-590-5p inhibits intestinal inflammation by targeting YAP. J Crohns Colitis. 12:993–1004. 2018. View Article : Google Scholar : PubMed/NCBI

50 

Dong L, Lin F, Wu W, Liu Y and Huang W: Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway. Int J Med Sci. 15:645–652. 2018. View Article : Google Scholar : PubMed/NCBI

51 

Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, et al: Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 13:3492013. View Article : Google Scholar : PubMed/NCBI

52 

van Kessel KE, Van Neste L, Lurkin I, Zwarthoff EC and Van Criekinge W: Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J Urol. 195:601–607. 2016. View Article : Google Scholar : PubMed/NCBI

53 

Zhang J, Zhou Y, Huang T, Wu F, Pan Y, Dong Y, Wang Y, Chan AK, Liu L, Kwan JS, et al: FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. Oncogene. 38:33–46. 2019. View Article : Google Scholar : PubMed/NCBI

54 

Marzi MJ, Ghini F, Cerruti B, de Pretis S, Bonetti P, Giacomelli C, Gorski MM, Kress T, Pelizzola M, Muller H, et al: Degradation dynamics of microRNAs revealed by a novel pulse-chase approach. Genome Res. 26:554–565. 2016. View Article : Google Scholar : PubMed/NCBI

55 

Gantier MP, McCoy CE, Rusinova I, Saulep D, Wang D, Xu D, Irving AT, Behlke MA, Hertzog PJ, Mackay F and Williams BR: Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res. 39:5692–5703. 2011. View Article : Google Scholar : PubMed/NCBI

56 

Guo Y, Liu J, Elfenbein SJ, Ma Y, Zhong M, Qiu C, Ding Y and Lu J: Characterization of the mammalian miRNA turnover landscape. Nucleic Acids Res. 43:2326–2341. 2015. View Article : Google Scholar : PubMed/NCBI

57 

Juracek J, Peltanova B, Dolezel J, Fedorko M, Pacik D, Radova L, Vesela P, Svoboda M, Slaby O and Stanik M: Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer. J Cell Mol Med. 22:2033–2038. 2018. View Article : Google Scholar : PubMed/NCBI

58 

Zhang X, Zhang Y, Liu X, Fang A, Wang J, Yang Y, Wang L, Du L and Wang C: Direct quantitative detection for cell-free miR-155 in urine: A potential role in diagnosis and prognosis for non-muscle invasive bladder cancer. Oncotarget. 7:3255–3266. 2016.PubMed/NCBI

59 

Du L, Jiang X, Duan W, Wang R, Wang L, Zheng G, Yan K, Wang L, Li J, Zhang X, et al: Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Oncotarget. 8:40832–40842. 2017. View Article : Google Scholar : PubMed/NCBI

60 

Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, et al: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 102:1174–1179. 2010. View Article : Google Scholar : PubMed/NCBI

61 

Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG and Zhang YK: Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol. 29:3190–3197. 2012. View Article : Google Scholar : PubMed/NCBI

62 

Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010. View Article : Google Scholar : PubMed/NCBI

63 

Aushev VN, Zborovskaya IB, Laktionov KK, Girard N, Cros MP, Herceg Z and Krutovskikh V: Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One. 8:e786492013. View Article : Google Scholar : PubMed/NCBI

64 

Leidinger P, Keller A, Backes C, Huwer H and Meese E: MicroRNA expression changes after lung cancer resection: A follow-up study. RNA Biol. 9:900–910. 2012. View Article : Google Scholar : PubMed/NCBI

65 

Leidinger P, Galata V, Backes C, Stähler C, Rheinheimer S, Huwer H, Meese E and Keller A: Longitudinal study on circulating miRNAs in patients after lung cancer resection. Oncotarget. 6:16674–16685. 2015. View Article : Google Scholar : PubMed/NCBI

66 

Egidi MG, Cochetti G, Serva MR, Guelfi G, Zampini D, Mechelli L and Mearini E: Circulating microRNAs and kallikreins before and after radical prostatectomy: Are they really prostate cancer markers? Biomed Res Int. 2013:2417802013. View Article : Google Scholar : PubMed/NCBI

67 

Keller A, Rounge T, Backes C, Ludwig N, Gislefoss R, Leidinger P, Langseth H and Meese E: Sources to variability in circulating human miRNA signatures. RNA Biol. 14:1791–1798. 2017. View Article : Google Scholar : PubMed/NCBI

68 

Aarsand AK, Roraas T, Fernandez-Calle P, Ricos C, Diaz-Garzon J, Jonker N, Perich C, Gonzalez-Lao E, Carobene A, Minchinela J, et al: The biological variation data critical appraisal checklist: A standard for evaluating studies on biological variation. Clin Chem. 64:501–514. 2018. View Article : Google Scholar : PubMed/NCBI

69 

Burke HB: Increasing the power of surrogate endpoint biomarkers: The aggregation of predictive factors. J Cell Biochem. (Suppl 19):S278–S282. 1994.

Related Articles

Journal Cover

October 2019
Volume 42 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tölle, A., Buckendahl, L., & Jung, K. (2019). Plasma miR‑15b‑5p and miR‑590‑5p for distinguishing patients with bladder cancer from healthy individuals. Oncology Reports, 42, 1609-1620. https://doi.org/10.3892/or.2019.7247
MLA
Tölle, A., Buckendahl, L., Jung, K."Plasma miR‑15b‑5p and miR‑590‑5p for distinguishing patients with bladder cancer from healthy individuals". Oncology Reports 42.4 (2019): 1609-1620.
Chicago
Tölle, A., Buckendahl, L., Jung, K."Plasma miR‑15b‑5p and miR‑590‑5p for distinguishing patients with bladder cancer from healthy individuals". Oncology Reports 42, no. 4 (2019): 1609-1620. https://doi.org/10.3892/or.2019.7247